Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (91-100 of 169) with videos related to

Pageof 17
Sort By:
Open Forum Infectious Diseases|June 5, 2020
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in InfantsMarta Valente Pinto, Daniel O'Connor, Ushma Galal, et al.
Vaccine|August 23, 2013
Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing scheduleGail L Rodgers, Susanna Esposito, Nicola Principi, et al.
Clinical and Vaccine Immunology : CVI|December 30, 2011
Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccineCatrin E Moore, Branwen J Hennig, Kirsten P Perrett, et al.
Vaccine|March 8, 2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsAmeneh Khatami, Matthew D Snape, Elizabeth Davis, et al.
Vaccine|June 13, 2022
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisationChristine S Rollier, Christina Dold, Luke Blackwell, et al.
The Pediatric Infectious Disease Journal|January 13, 2016
Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of AgeMatthew D Snape, Merryn Voysey, Adam Finn, et al.
The Pediatric Infectious Disease Journal|February 12, 2009
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infantsKirsten P Perrett, Matthew D Snape, Karen J Ford, et al.
Acta Obstetricia Et Gynecologica Scandinavica|January 3, 2018
Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the UK towards participation in clinical trials and routine implementationFiona McQuaid, Christine Jones, Zoe Stevens, et al.
BMJ Open|July 1, 2019
Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocolAnette-Gabriele Ziegler, Peter Achenbach, Reinhard Berner, et al.
Lancet (London, England)|December 23, 2021
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serumWanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa, et al.
Pageof 17

Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Open Forum Infectious Diseases|June 5, 2020
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in InfantsMarta Valente Pinto, Daniel O'Connor, Ushma Galal, et al.
Vaccine|August 23, 2013
Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing scheduleGail L Rodgers, Susanna Esposito, Nicola Principi, et al.
Clinical and Vaccine Immunology : CVI|December 30, 2011
Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccineCatrin E Moore, Branwen J Hennig, Kirsten P Perrett, et al.
Vaccine|March 8, 2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsAmeneh Khatami, Matthew D Snape, Elizabeth Davis, et al.
Vaccine|June 13, 2022
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisationChristine S Rollier, Christina Dold, Luke Blackwell, et al.
The Pediatric Infectious Disease Journal|January 13, 2016
Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of AgeMatthew D Snape, Merryn Voysey, Adam Finn, et al.
The Pediatric Infectious Disease Journal|February 12, 2009
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infantsKirsten P Perrett, Matthew D Snape, Karen J Ford, et al.
Acta Obstetricia Et Gynecologica Scandinavica|January 3, 2018
Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the UK towards participation in clinical trials and routine implementationFiona McQuaid, Christine Jones, Zoe Stevens, et al.
BMJ Open|July 1, 2019
Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocolAnette-Gabriele Ziegler, Peter Achenbach, Reinhard Berner, et al.
Lancet (London, England)|December 23, 2021
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serumWanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa, et al.
Pageof 17